Annual Revenue Comparison: Pfizer Inc. vs Takeda Pharmaceutical Company Limited

Pfizer vs. Takeda: A Decade of Revenue Dynamics

__timestampPfizer Inc.Takeda Pharmaceutical Company Limited
Wednesday, January 1, 2014496050000001777824000000
Thursday, January 1, 2015488510000001807378000000
Friday, January 1, 2016528240000001732051000000
Sunday, January 1, 2017525460000001770531000000
Monday, January 1, 2018536470000002097224000000
Tuesday, January 1, 2019517500000003291188000000
Wednesday, January 1, 2020419080000003197812000000
Friday, January 1, 2021812880000003569006000000
Saturday, January 1, 20221003300000004027478000000
Sunday, January 1, 2023584960000004263762000000
Monday, January 1, 2024636270000004263762000000
Loading chart...

Cracking the code

A Tale of Two Pharmaceutical Giants: Pfizer vs. Takeda

In the ever-evolving landscape of global pharmaceuticals, Pfizer Inc. and Takeda Pharmaceutical Company Limited stand as titans. Over the past decade, Takeda's revenue has consistently dwarfed Pfizer's, with Takeda's 2023 revenue reaching approximately 4.26 trillion, nearly 7 times Pfizer's 58.5 billion. This trend highlights Takeda's robust growth, especially since 2018, when its revenue surged by over 100%.

Pfizer, however, experienced a notable spike in 2021, with revenues increasing by nearly 94% from the previous year, likely driven by its COVID-19 vaccine success. Despite this, Pfizer's revenue in 2023 fell back to pre-pandemic levels, indicating a potential stabilization post-vaccine boom.

As we look to the future, the absence of Pfizer's 2024 data leaves room for speculation. Will Pfizer regain momentum, or will Takeda continue its dominance? Only time will tell.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025